Introduction
Brocef 250 is an antibiotic medicine used to treat bacterial infections in your body. It is effective in infections of the lungs (e.g. pneumonia), ear, throat, nasal sinus, urinary tract, skin, soft tissues, bones, and joints. It is also used to prevent infections during surgery.
Brocef 250 is given as a drip (intravenous infusion) or as an injection directly into a vein or a muscle under the supervision of a healthcare professional. Your doctor will decide the correct dose for you. You should use this medicine regularly at evenly spaced intervals as per the schedule prescribed by your doctor. Do not skip any doses and finish the full course of treatment even if you feel better. Stopping the medicine too early may lead to the infection returning or worsening.
The most common side effects of this medicine include rash, vomiting, diarrhea, increased liver enzymes and nausea. Some people may develop temporary redness or pain at the site of injection. These side effects are usually mild but let your doctor know if they bother you or last more than a few days.
Before using it, you should tell your doctor if you are allergic to any antibiotics, and if you have any liver or kidney problems. You should also let your doctor know all other medicines you are taking as they may affect, or be affected by this medicine. Pregnant and breastfeeding mothers should consult their doctor before using it.
Side effects of Brocef 250
Common
- Rash
- Vomiting
- Allergic reaction
- Increased liver enzymes
- Nausea
- Injection site reaction
- Diarrhea
How to use Brocef 250
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Brocef 250 works
Brocef 250 is an antibiotic. It kills bacteria by preventing them from forming the bacterial protective covering (cell wall) which is needed for them to survive.
What if you forget to take Brocef 250?
If you miss a dose of Brocef 250, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
Indication
Pharyngitis, Acute otitis media, Lyme disease, Susceptible infections, Sinusitis, Otitis media, Skin and skin structure infections,Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Urinary tract infections, Acute bacterial exacerbation of chronic bronchitis, Surgical Prophylaxis
Administration
Tab: May be taken with or without food.
Oral susp: Should be taken with food.
IV Preparation
Direct injection: reconstitute in 8 mL (for 750-mg vial) or 16 mL (for 1.5-g vial) to obtain ~90 mg/mL solution
Infusion: Reconstitute in 100 mL SWI, D5W or NS to obtain 7.5 mg/mL (750-mg vial) or 15 mg/mL (1.5-g vial) solution
7.5 g bulk package not to be used for direct injection
IM Preparation
Reconstitute 750 mg in 3 mL SWI to obtain ~220 mg/mL solution
IV Administration
Direct injection: Inject directly into vein over 3-5 minutes or slowly into tubing of free-flowing compatible IV solution
Infusion: Infuse intermittently over 15-60 minutes
Adult Dose
Pharyngitis/Tonsillitis
250 mg PO q12hr for 10 days
Acute Bacterial Maxillary Sinusitis
250 mg PO q12hr for 10 days
Acute Bacterial Exacerbations of Chronic Bronchitis
250-500 mg PO q12hr for 10 days
500-750 mg IV q8hr; switch to oral therapy as soon as clinically possible
Secondary Bacterial Infections of Acute Bronchitis
250-500 mg PO q12hr for 5-10 days
Uncomplicated Pneumonia
750 mg IV/IM q8hr
Uncomplicated Skin/Skin Structure Infections
250-500 mg PO q12hr for 10 days
750 mg IV/IM q8hr; switch to oral therapy as soon as clinically possible
Uncomplicated Urinary Tract Infections
125-250 mg PO q12hr for 7-10 days
750 mg IV/IM q8hr; switch to oral therapy as soon as clinically possible
Gonorrhea
Uncomplicated: 1 g PO once or 1.5 g IM once at 2 different sites with 1 g probenecid PO
Disseminated: 750 mg IV/IM q8hr
Early Lyme Disease
500 mg PO q12hr for 20 days
Severe or Complicated Infections
1.5 g IV/IM q8hr; may be administered q6hr in life-threatening situations
Oral
Susceptible infections
Adult: 250 mg bid.
Parenteral
Susceptible infections
Adult: 0.75 g 8 hrly, by deep IM or slow IV inj over 3-5 min or IV infusion, may increase up to 1.5 g 6-8 hrly in more severe infections.
Child Dose
Children: PO 20–30 mg/kg/day q12h
For bone and joint infections, up to 100 mg/kg/day
IV, IM 100–150 mg/kg/day q8h
Renal Dose
Renal impairment: Patients undergoing haemodialysis should receive an additional 750-mg dose after each dialysis; those undergoing continuous peritoneal dialysis may be given 750 mg bid.
CrCl (ml/min)
10-20 750 mg bid.
<10 750 mg once daily.
Contraindication
Hypersensitivity to cephalosporins.
Mode of Action
Cefuroxime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Precaution
Severe renal impairment; pregnancy, lactation; hypersensitivity to penicillins.
Lactation: Drug excreted in breast milk; use with caution
Side Effect
>10%
Diarrhea (4-11%; depends on duration)
1-10%
Decreased hemoglobin or hematocrit (10%),Eosinophilia (7%),Nausea or vomiting (3-7%),Vaginitis (<5%),Transient rise in hepatic transaminases (2-4%),Diaper rash (3%),Increase in alkaline phosphatase (2%),Thrombophlebitis (2%),Increase in lactate dehydrogenase (1%)
<1%
Anemia,Cholestasis,Colitis,Dyspnea,Epidermal necrolysis,Increase in blood urea nitrogen (BUN) and creatinine,Jaundice,Nephritis,Prolonged prothrombin time (PT)/international normalized ratio (INR),Rash,Stevens-Johnson syndrome,Stomach cramps,Transient neutropenia and leukopenia,Urticaria
Potentially Fatal: Anaphylaxis, nephrotoxicity, pseudomembranous colitis.
Pregnancy Category Note
Pregnancy
Available data from published epidemiologic studies, case series, and case reports over several decades in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes
Lactation
Based on several published case reports describing multiple lactating women receiving therapy via intravenous, intramuscular, and oral routes, drug is present in human milk; the highest maternal milk concentration described occurred in lactating women 8 hours after an intramuscular administration of 750 mg; allowing for an infant milk consumption of 150 mL/kg/day, the estimated breastfed infant dose would be less than 1% of adult dose
No data are available on effects of drug on breastfed infant or on milk production; developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal condition
Interaction
May enhance the nephrotoxic effect of strong-acting diuretics (e.g. furosemide) and aminoglycosides. May enhance the effect of oral anticoagulants. May reduce the efficacy of OCs. Probenecid prolongs the excretion of cefuroxime and elevated peak serum level.
